文献速递神经免疫

抗NMDAR脑炎:机制与模型更新

An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models.
PubMed 文献 · Lancet Neurol · 2019-07-17

该综述指出抗NMDAR脑炎可表现为快速进展的精神症状、认知障碍、癫痫、异常运动或昏迷,自身抗体是诊断标志物并改变突触传递。女性约占8:2,约37%患者发病时小于18岁,肿瘤(多为卵巢畸胎瘤)和单纯疱疹脑炎是已知诱因。约80%患者经免疫治疗及必要时肿瘤切除后改善,但恢复缓慢;动物模型正揭示复杂机制并有望带来新治疗。

要点

  • 抗NMDAR脑炎可表现为精神症状、认知障碍、癫痫、异常运动或昏迷,需与原发性精神障碍鉴别。
  • 女性约占8:2,约37%患者发病时小于18岁。
  • 约80%患者经免疫治疗及必要时肿瘤切除后改善,但恢复缓慢。

核心结论

  • 约80%抗NMDAR脑炎患者经免疫治疗及必要时肿瘤切除后改善,但恢复缓慢。

研究设计与样本

  • 综述总结了抗NMDAR脑炎的临床特征、致病机制及动物模型研究进展。

主要发现

  • 抗NMDAR脑炎女性约占8:2,约37%患者发病时小于18岁。
  • 肿瘤(通常为卵巢畸胎瘤)和单纯疱疹脑炎是NMDAR自身免疫的已知诱因。
  • 自身抗体作为诊断标志物并改变NMDAR相关突触传递。
  • 除临床评估外,尚无特异性预后生物标志物。

临床怎么用

  • 对快速进展的精神症状、认知障碍、癫痫、异常运动或不明原因昏迷者应识别自身免疫性脑炎可能。
  • 确诊后应给予免疫治疗,必要时行肿瘤切除。

局限性

  • 发病初期难以与原发性精神障碍区分。
  • 症状严重常需重症监护。
  • 尚无特异性预后生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The identification of anti-NMDA receptor (NMDAR) encephalitis about 12 years ago made it possible to recognise that some patients with rapidly progressive psychiatric symptoms or cognitive impairment, seizures, abnormal movements, or coma of unknown cause, had an autoimmune disease. In this disease, autoantibodies serve as a diagnostic marker and alter NMDAR-related synaptic transmission. At symptom onset, distinguishing the disease from a primary psychiatric disorder is challenging. The severity of symptoms often requires intensive care. Other than clinical assessment, no specific prognostic biomarkers exist. The disease is more prevalent in women (with a female to male ratio of around 8:2) and about 37% of patients are younger than 18 years at presentation of the disease. Tumours, usually ovarian teratoma, and herpes simplex encephalitis are known triggers of NMDAR autoimmunity. About 80% of patients improve with immunotherapy and, if needed, tumour removal, but the recovery is slow. Animal models have started to reveal the complexity of the underlying pathogenic mechanisms and will lead to novel treatments beyond immunotherapy. Future studies should aim at identifying prognostic biomarkers and treatments that accelerate recovery.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019. PMID: 31326280. doi:10.1016/S1474-4422(19)30244-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。